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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To review the time to withdrawal, remission and first seizure of 10 antiepileptic drugs (carbamazepine, phenytoin, valproate, pheno-
barbitone, oxcarbazepine, lamotrigine, gabapentin, topiramate, levetiracetam, zonisamide) currently used as monotherapy in children
and adults with partial onset seizures or generalised tonic-clonic seizures with or without other generalised seizure types.
B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological condition in which recurrent,
unprovoked seizures are caused by abnormal electrical discharges
from the brain. Epilepsy is a disorder ofmany heterogenous seizure
types, with an estimated incidence of 33 to 57 per 100,000 person-
years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000;
Olafsson 2005; Sander 1996), accounting for approximately 1%
of the global burden of disease (WHO 1994). The lifetime risk of
epilepsy onset is estimated to be 1300 to 4000 per 100,000 person
years (Hauser 1993; Juul-Jenson 1983), and the lifetime preva-
lence could be as large as 70 million people world-wide (Ngugi
2010). It is believed that with effective drug treatment, up to 70%
of individuals with active epilepsy have the potential to become
seizure free and go into long-term remission shortly after starting
drug therapy (Cockerell 1995; Hauser 1993; Sander 2004), and
that around 70% of individuals can achieve seizure freedom using
a single antiepileptic drug in monotherapy (Cockerell 1995). The
remaining 30% of individuals experience refractory or drug re-
sistant seizures which often require treatment with combinations
of antiepileptic drugs or alternative treatments such as epilepsy
surgery (Kwan 2000).
We will study two seizure types in this review; generalised onset
seizures in which electrical discharges begin in one part of the
brain and move throughout the brain, and partial onset seizures in
which the seizure is generated in and affects one part of the brain
(the whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
For the treatment of partial and generalised onset seizures we will
include in our evidence base the following 10 antiepileptic drugs,
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which are currently licensed and used in clinical practice for use
as monotherapy in at least one country (eMC 2014; FDA 2014):
• carbamazepine;
• phenytoin;
• valproate;
• phenobarbitone;
• oxcarbazepine;
• lamotrigine;
• gabapentin;
• topiramate;
• levetiracetam;
• zonisamide.
Carbamazepine, valproate, phenytoin and phenobarbitone are
among the earliest traditional drugs licensed in the treatment of
epileptic seizures. Carbamazepine and valproate have been com-
monly used as monotherapy for partial onset and generalised on-
set seizures for over 30 years (Shakir 1980), while phenytoin and
phenobarbitone have been used in monotherapy for over 50 years
(Gruber 1962).
These traditionally used drugs have all been recommended as first-
line treatments due to their broad therapeutic anticonvulsant ef-
fect. However, the drugs are also associated with a number of ad-
verse effects. Phenytoin and phenobarbitone are no longer consid-
ered as first-line agents in the United States and much of Europe
due to worries over adverse events (Wallace 1997; Wilder 1995).
Both drugs have been shown to be teratogenic (associated with
malformations of an embryo or foetus) and are associated with
low folic acid levels and megaloblastic anaemia; a blood disorder
marked by the appearance of very large red blood cells (Carl 1992;
Gladstone 1992; Meador 2008; Morrow 2006; Nulman 1997).
PHT is particularly associated with “fetal hydantoin syndrome”,
the name given to a group of birth defects associated with exposure
to phenytoin (Scheinfeld 2003), and phenobarbitone has been as-
sociated with behavioural disturbances particularly in children (de
Silva 1996; Trimble 1988). These agents are however still used
as first-line drugs in low to middle-income countries (Ogunrin
2005; Pal 1998).
Carbamazepine and valproate are also associated with congeni-
tal abnormalities (Canger 1999; Gladstone 1992; Morrow 2006;
Nulman 1997; Tomson 2011). A systematic review found val-
proate to have the highest incidence of congenital malformations
of traditional first-line antiepileptic drugs (Meador 2008), partic-
ularly spina bifida as well as cardiac, craniofacial, skeletal and limb
defects known as ’valproate syndrome’ (Ornoy 2009). A recent
study has shown an increased prevalence of neurodevelopmental
disorders following prenatal valproate exposure (Bromley 2013).
In the last 20 years, a second-generation of antiepileptic drugs in-
cluding oxcarbazepine, lamotrigine, gabapentin, topiramate and
most recently levetiracetam and zonisamide have been licensed
as monotherapy following demonstrations of efficacy compared
to the traditional antiepileptic drugs (Baulac 2012; Bill 1997;
Brodie 1995; Brodie 1999; Brodie 2007; Chadwick 1998; Christe
1997;Dam1989;Guerreiro 1997;Marson 2007a;Marson 2007b;
Privitera 2003; Reunanen 1996; Rowan 2005; Steiner 1999;
Trinka 2012). Comparative studies have also shown the newer
antiepileptic drugs to be generally well tolerated as monotherapy
in both adults and children and related to fewer adverse events,
fewer serious adverse events, fewer teratogenic effects and fewer
drug interactions with concomitant antiepileptic drugs and other
concomitant medications than the traditional first-line antiepilep-
tic drugs (French 2004; French 2007).
Current guidelines from the National Institute for Health and
Care Excellence (NICE) for adults and children recommend car-
bamazepine or lamotrigine as first-line treatment for partial onset
seizures and valproate for generalised onset seizures, on the condi-
tion that women and girls of childbearing are made aware of the
potential teratogenic effects of the drug (NICE 2012).
How the intervention might work
Antiepileptic drugs suppress seizures by reducing neuronal ex-
citability (disruption of the usual mechanisms of a neuron within
the brain which may lead to an epileptic seizure). Different
antiepileptic drugs have different mechanisms of action; therefore
certain antiepileptic drugs are more effective at treating different
seizure types. For example, there are reports of efficacy for valproate
in generalised epilepsy syndromes such as juvenile myoclonic
epilepsy and absence epilepsy (Bourgeois 1987; Delgado-Escueta
1984; Grünewald 1993; Jeavons 1977; Penry 1989), while car-
bamazepine on the other hand is reported to exacerbate some
generalised seizure types such as myoclonic and absence seizures
(Liporace 1994; Shields 1983; Snead 1985).
The majority of traditional antiepileptic drugs are thought to have
multiplemechanisms of action such as through blocking ion chan-
nels, binding with neurotransmitter receptors or through inhibit-
ing the metabolism or reuptake of neurotransmitters. However
the precise mechanism of action is not known for all antiepilep-
tic drugs, particularly valproate. It is thought that one of the
mechanisms of action of phenytoin, valproate, carbamazepine,
oxcarbazepine and lamotrigine is via blocking of sodium chan-
nels (Dichter 1996; Faigle 1990; Granger 1995; Grant 1992;
Lees 1993; McLean 1986; Pinder 1977; Ragsdale 1991; Willow
1985), while phenobarbitone binds with gamma-aminobutyric
acid (GABA) A receptors (Rho 1996). The similar anticonvulsant
mechanisms of these drugsmake thembroad-spectrum treatments
for many seizure types.
Zonisamide is thought to have multiple mechanisms of action
(Endoh 1994; Kawai 1994; Okada 1998; Sackellares 2004; Schauf
1987; Suzuki 1992; Zhu 1999), while the mechanism of actions
of gabapentin and topiramate are not fully understood (Coulter
1993; Dichter 1996; Hill 1993; McClean 1995; McLean 1999;
White 1997). Levetiracatam has a novel mode of action which is
different from that of other antiepileptic drugs (Cho 2011); it is
thought to exhibit its antiepileptic effect by binding to synaptic
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vesicle protein 2A (encoded within the SV2A gene), influencing
excitatory neurotransmitter release (Gillard 2006; Lynch 2004).
Why it is important to do this review
With evidence that up to 70% of individuals with active epilepsy
have the potential to go into long term remission of seizures shortly
after starting drug therapy (Cockerell 1995; Hauser 1993; Sander
2004), the correct choice of first-line antiepileptic therapy for in-
dividuals with newly diagnosed seizures is of great importance.
There are currently over 50 drugs available worldwide for the treat-
ment of various seizure types (Epilepsy Foundation of America
2013), therefore it is important that the choice of antiepileptic
drugs for an individual is made using the highest quality evidence
regarding potential benefits and harms of various treatments. It
is also important that effectiveness and tolerability of antiepilep-
tic drugs appropriate to given seizure types are compared to one
another. For the treatment of partial and generalised onset tonic
clonic seizures we will include in our evidence base the following
10 antiepileptic drugs which are currently licensed and used in
clinical practice for use as monotherapy in at least one country:
1. carbamazepine;
2. phenytoin;
3. valproate;
4. phenobarbitone;
5. oxcarbazepine;
6. lamotrigine;
7. gabapentin;
8. topiramate;
9. levetiracetam;
10. zonisamide.
We have published a series of Cochrane systematic reviews inves-
tigating pairwise monotherapy comparisons using individual par-
ticipant data (Gamble 2009; Marson 2000; Nolan 2013a; Nolan
2013b; Nolan 2013c; Tudur Smith 2009; Tudur Smith 2010).
Each Cochrane review and meta-analysis provides high quality ev-
idence for each pair of drugs but does not inform a choice between
the whole evidence base of appropriate drugs for decision mak-
ers, clinicians or individuals with epilepsy. Furthermore, direct ev-
idence from randomised controlled trials (RCTs) is not available
between some of the drugs in our evidence base (such as between
oxcarbazepine and phenobarbitone); therefore it is not possible to
make pairwise comparisons of treatment effects between all ten
drugs. Pairwise comparisons between certain drugs are unlikely to
be made in the future; for example as phenobarbitone is no longer
considered to be a first-line treatment as monotherapy for epilepsy,
it is unlikely that a RCT will be designed in the future to compare
oxcarbazepine with phenobarbitone (Tudur Smith 2007). How-
ever, it is possible to estimate an indirect treatment effect size be-
tween OXC and phenobarbitone by using existing evidence com-
paring oxcarbazepine with phenytoin and phenytoin with pheno-
barbitone (Nolan 2013a; Nolan 2013b). By similar methodology,
an indirect pairwise comparison is possible for all ten drugs in our
treatment network. Indirect comparisons are also valuable in the
case that a limited amount of data is available to inform a direct
comparison or in the case that evidence informing a direct com-
parison is of poor methodological quality. The power and preci-
sion of a treatment effect estimate can be increased by “borrowing
strength” from the indirect evidence in the network of treatments
(Bucher 1997). Eight of the antiepileptic drugs included in this
review have been included in an IPD network meta-analysis of
epilepsy monotherapy drugs (Tudur Smith 2007). We wish to up-
date the information in this network meta-analysis with new evi-
dence from studies published since 2007 and including evidence
for two drugs which were licensed for use as monotherapy after
2007.
As noted in the series of Cochrane reviews investigating pairwise
monotherapy comparisons, the important efficacy outcomes in
epilepsymonotherapy trials often require analysis of time-to-event
data (for example, time to first seizure after randomisation or time
to withdrawal of allocated treatment). Although methods have
been developed to synthesise time-to-event data using summary
information (Parmar 1998; Williamson 2002), the appropriate
statistics are not commonly reported in published epilepsy trials
(Altman 1995; Nolan 2013).
Furthermore, although seizure data have been collected in most
epilepsy monotherapy trials, we have seen little uniformity in the
definition and reporting of outcomes. For example, trials may re-
port time to 12month remissionbut not time to first seizure or vice
versa or some trials may define time to first seizure from the date
of randomisation but others use date of achieving maintenance
dose. Trial investigators have also adopted differing approaches to
the analysis, particularly with respect to the censoring of time-to-
event data. For these reasons, we performed the pairwise meta-
analyses using IPD which helps to overcome these problems and
is considered to be the ’gold standard’ approach to synthesis of
censored data (Parmar 1998). We will therefore also perform the
network meta-analysis of epilepsy monotherapy drugs as an IPD
analysis.
O B J E C T I V E S
To review the time to withdrawal, remission and first seizure of
10 antiepileptic drugs (carbamazepine, phenytoin, valproate, phe-
nobarbitone, oxcarbazepine, lamotrigine, gabapentin, topiramate,
levetiracetam, zonisamide) currently used as monotherapy in chil-
dren and adults with partial onset seizures or generalised tonic-
clonic seizures with or without other generalised seizure types.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We will include RCTs using either:
• an adequate method of allocation concealment (e.g. sealed
opaque envelopes);
• a quasi method of randomisation (e.g. allocation by date of
birth).
Studies may be double-blind, single-blind or unblinded. We will
exclude studies of a monotherapy design; in other words partici-
pants are randomised to treatment with a single drug throughout
the study period. We will also exclude studies with an add-on,
polytherapy, transitional or withdrawal to monotherapy periods
of any length.
Wewill include studies of parallel designs will be included.Wewill
exclude studies of a cross-over design as we believe this design is
inappropriate for measuring our primary time-to-event outcome
’time to withdrawal of allocated treatment’ as a withdrawal of
allocated treatment in the first treatment period would mean than
the participant could not cross into the second treatment period,
potentially leading to a large amount of incomplete outcome data
and therefore a reduction in statistical power. Furthermore, the use
of cross-over designs is no longer recommended in epilepsy due
to concerns over study duration, large proportions of dropouts,
unblinding of masked treatments as participants cross into the
second period and potential carryover effects; a particular concern
in studies of a monotherapy design which aim to assess the effect
of a single treatment (Engel 2008; Wyllie 2006).
Types of participants
Children or adults with partial onset seizures (simple partial, com-
plex partial, or secondarily generalised tonic-clonic seizures) or
generalised onset tonic-clonic seizures (with or without other gen-
eralised seizure types). We will not include participants with other
generalised seizure types alone (for example absence seizures alone
without generalised tonic clonic seizures) as guidelines for the first-
line treatment of other generalised seizure types are often different
from the guidelines for generalised tonic-clonic seizures (NICE
2012), and due to documented evidence that certain drugs of in-
terest in our review may exacerbate some generalised seizure types
(How the interventions might work). We will also consider indi-
viduals with a new diagnosis of epilepsy, or who had had a relapse
following antiepileptic monotherapy withdrawal.
We will exclude studies which consider antiepileptic drugs as treat-
ment for conditions other than epilepsy.
Types of interventions
We will include the 10 antiepileptic drugs currently licensed
and used as monotherapy in our network of treatments: carba-
mazepine, phenytoin, valproate, phenobarbitone, oxcarbazepine,
lamotrigine, gabapentin, topiramate, levetiracetam, zonisamide.
Included studies must make at least one pairwise comparison be-
tween at least 2 of the 10 antiepileptic drugs included in our net-
work. For studies with three treatment arms or more, we will in-
clude treatment arms only of the 10 antiepileptic drugs included
in our network; treatment arms of drugs not included in our net-
work will be excluded from analysis. We will not make pairwise
comparisons (direct or indirect) between any antiepileptic drugs
not specified above. We will make pairwise comparisons (based
on direct and/or indirect evidence) between all 10 drugs (Data
synthesis).
Types of outcome measures
Wewill investigate the following outcomes in this review (Primary
outcomes; Secondary outcomes). Reporting of these outcomes in
the original trial report is not an eligibility requirement for inclu-
sion in this review.
Primary outcomes
Time to withdrawal of allocated treatment (retention time). This
is a combined outcome reflecting both efficacy and tolerability as
treatment may be withdrawn due to continued seizures, adverse
effects or a combination of both. This is an outcome to which
the participant makes a contribution, and is the primary out-
come measure recommended by the Commission on Antiepilep-
tic Drugs of the International League Against Epilepsy (Glauser
2006; ILAE Commission on Antiepileptic Drugs 1998)
Secondary outcomes
1. Time to achieve 12 month seizure-free period (remission)
after randomisation
2. Time to achieve six month seizure-free period (remission)
after randomisation
3. Time to first seizure post randomisation
4. Occurrence of adverse events (to be reported narratively)
(Data synthesis)
Search methods for identification of studies
We will search the following databases with no language restric-
tions:
• the Cochrane Epilepsy Group Specialised Register using the
search strategy outlined in Appendix 1;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) using the search strategy outlined in Appendix 2;
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• MEDLINE using the search strategy outlined in Appendix
3;
• SCOPUS using the search strategy outlined in Appendix 4;
• ClinicalTrials.gov (http://clinicaltrials.gov/) using the
search terms ’(Carbamazepine OR Phenytoin OR Valproic Acid
OR Phenobarbital OR Oxcarbazepine OR Lamotrigine OR
Gabapentin OR Topiramate OR Levetiracetam OR Zonisamide)
AND epilepsy’;
• (the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal (http://
apps.who.int/trialsearch/), using the search terms
’(Carbamazepine OR Phenytoin OR Valproic Acid OR
Phenobarbital OR Oxcarbazepine OR Lamotrigine OR
Gabapentin OR Topiramate OR Levetiracetam OR Zonisamide)
AND epilepsy’.
We will also review reference lists of retrieved studies to search for
additional reports of relevant studies and review relevant confer-
ence proceedings and contact experts in the field for details of any
ongoing or unpublished studies.
Data collection and analysis
Selection of studies
One author (SJN) will screen all titles and abstracts of all studies
identified by the electronic searches as described in Search methods
for identification of reviews according to the inclusion criteria
specified above (Types of studies; Types of participants; Types of
interventions). Subsequently, two authors (SJN and AGM) will
independently assess full-text publications according to the same
inclusion criteria specified above.We will resolve disagreements by
discussion or by consulting a third author (CT) where necessary.
We will record the reasons for exclusion of studies at both stages
of study selection. We will contact trial authors for clarification if
eligibility of a study is unclear from the published information.
Data extraction and management
For all studies meeting our inclusion criteria, two authors (SJN
and AGM) will send a data request form to the first and/or cor-
responding author of the study or to the study sponsor where ap-
propriate (referred to as data providers herein).
Our data request form will ask the data providers if the following
information is available (tick yes or no).
• Trial methods:
◦ method of generation of random list;
◦ method of concealment of randomisation;
◦ stratification factors;
◦ blinding methods.
• Participant covariates:
◦ sex;
◦ age;
◦ seizure types;
◦ epilepsy status (newly diagnosed / relapsed seizures
following drug withdrawal);
◦ time between first seizure and randomisation;
◦ number of seizures prior to randomisation (with
dates);
◦ presence of neurological signs;
◦ electroencephalography (EEG) results;
◦ computed tomography (CT) or magnetic resonance
imaging (MRI) results;
◦ aetiology of seizures (if known).
• Follow-up data:
◦ treatment allocation;
◦ date of randomisation;
◦ dates of follow up;
◦ dates of seizures post randomisation or seizure
frequency data between follow-up visits;
◦ dates of treatment withdrawal and reason(s) for
treatment withdrawal;
◦ starting dose of treatment;
◦ dates of dose changes;
◦ adverse events reported.
We will also request for any available, related documents such as
case report forms, study protocols, clinical summaries from data
providers.
In the event of no response to our IPD request, we will send a
follow-up e-mail to the original data provider contacted. If we
still receive no response for a particular study we will attempt to
contact another study author or sponsor where appropriate. If a
data provider is unable to make IPD available to us, we will request
any aggregate data related to our outcome not reported in the
publication.
If data cannot be obtained (no response to any requests or IPD is
not available), two independent authors (SJN and MS) will assess
whether any relevant and appropriate aggregate level data has been
reported in the trial publication.Wewill resolve any disagreements
on extracted aggregate data by discussion or by consulting a third
author (CT) if necessary.
Wewill store all obtained data on a secure, dedicated network drive
accessible only to the statisticians performing analysis (SJN, MS,
CT). We will check all provided data for consistency and prepare
them for analysis according to a pre-specified procedure prepared
by one author (SJN) (available on request) and piloted by two
authors (SJN and MS). For each trial where IPD are supplied, we
will reproduce results from trial findings where possible and we
will perform the following consistency checks:
• trial details cross-checked against any published report of
the trial; original trial authors to be contacted if missing data,
errors or inconsistencies are found;
• review of the chronological randomisation sequence by
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checking the balance of prognostic factors, taking account of
factors stratified for in randomisation procedure.
We will discuss any inconsistencies in the provided data with the
corresponding data providers. If large or major inconsistencies
are present which cannot be resolved by data providers, we will
not include the data in any analyses. If minor inconsistencies are
present, we will analyse the data and conduct sensitivity analyses
to test the robustness of results (Sensitivity analysis).
For the analysis of time to withdrawal of allocated treatment as
a time-to-event outcome, we define an ’event’ as either the with-
drawal of the allocated treatment due to poor seizure control or
adverse events or both. Non-compliance with the treatment reg-
imen or the addition of another antiepileptic drug will also be
classed as ’events’. The outcome will be censored if treatment was
withdrawn because the individual achieved a period of remission,
if a participant withdrew from allocated treatment for reasons not
related to the treatment (such as loss to follow-up) or if the in-
dividual was still on allocated treatment at the end of follow-up.
Two authors (SJN and AG) will independently review reasons for
treatment withdrawal for classification as events or censored ob-
servations, and we will resolve any disagreements by mutual dis-
cussion or by involving a third author (CT).
If seizure data are provided or recorded in terms of the number
of seizures recorded between clinic visits rather than specific dates
of seizures, to enable time-to-event outcomes to be calculated, we
will apply linear interpolation to approximate the dates on which
seizures occurred. For example, if four seizures were recorded be-
tween two visits which occurred on March 1st and May 1st (an
interval of 61 days), then date of first seizure would be approxi-
mately March 13th. This will allow an estimate of the time to six-
month and 12-month remission and the time to first seizure to be
computed.
Wewill calculate time to six-month and 12-month remission from
the date of randomisation to the date (or estimated date) the in-
dividual had first been free of seizures for six or 12 months re-
spectively. If the person had one or more seizures in the titration
period, a six-month or 12-month seizure-free period could also
occur between the estimated date of the last seizure in the titration
period and the estimated date of the first seizure in the mainte-
nance period
We will calculate time to first seizure from the date of randomi-
sation to the date that their first seizure was estimated to have
occurred. If seizure data are missing for a particular visit, these
outcomes will be censored at the previous visit. These outcomes
will also be censored if the individual died or if follow-up ceased
prior to the occurrence of the event of interest.
Assessment of risk of bias in included studies
Two independent authors (SJN, JW) will assess risk of bias in all
included trials using the Cochrane Collaboration’s tool for assess-
ing risk of bias (Higgins 2011). The following methodological cri-
teria are assessed according to this tool:
• selection bias (sequence generation and allocation
concealment);
• performance bias (blinding of participants and personnel);
• detection bias (blinding of outcome assessment);
• attrition bias (incomplete outcome data);
• reporting bias (selective outcome reporting).
We will resolve any disagreements by discussion. In theory, a re-
view using IPD should overcome issues of reporting biases as un-
published data can be provided and unpublished outcomes cal-
culated. Any selective reporting bias detected could be assessed
with the Outcome Reporting Bias in Trials (ORBIT) classifica-
tion system (Kirkham 2010). As specified in Data extraction and
management, we will ask the data providers to provide trial meth-
ods such as randomisation and blinding methods, and we will dis-
cuss any missing data and/or inconsistencies with them.
Wewill conduct sensitivity analyses by excluding any study judged
to be at high risk of bias for any methodological aspect (Sensitivity
analysis).
Measures of treatment effect
We will summarise all time-to-event outcomes using the hazard
ratio (HR) as the measure of treatment effect. We will calculate
outcomes from IPD provided where possible or extract them from
published studies. We will not attempt to analyse or synthesise
adverse event data; a large range of different adverse events are
thought to be associated with the 10 different drugs and such data
is generally collected and presented in different ways across studies.
For these reasons, we believe a synthesis of adverse event datawould
present only selective information while a narrative description of
adverse event data from IPD or extracted from published studies
will be the most informative way of presenting this data.
Unit of analysis issues
We do not anticipate any unit of analysis issues. For inclusion in
the review, the unit of allocation must be individual and studies of
a repeated measures (longitudinal) nature or of a cross-over design
are not eligible for inclusion
Dealing with missing data
For all included studies, we will conduct an assessment of the pro-
portion of missing outcome, demographic and covariate data and
make a judgement regarding the extent and nature of missing data
(e.g. missing at random, missing not at random). We will attempt
to contact all study authors in order to request relevant data; we
will include any information regarding missing data in such re-
quests (Data extraction and management). If further information
regarding missing data cannot be provided and we judge that an
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important proportion of data (particularly outcome data) is miss-
ing, wewill conduct sensitivity analyses to investigate the potential
impact of themissing data (for example best case scenario or worst
case scenario analyses, assuming those with missing outcome data
all have a favourable/unfavourable outcome, respectively).
Assessment of heterogeneity
Wewill use a fixed-effect model for all pairwise and networkmeta-
analyses in the first instance (Data synthesis). For each pairwise
comparison , we will assess the presence of heterogeneity statisti-
cally using the Q test (P value < 0.10 for significance) and the I2
statistic with the following interpretation (Higgins 2003).
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We will also assess the presence of heterogeneity by visually in-
specting forest plots, particularly in terms of the magnitude and
direction of effects. If considerable heterogeneity is found to be
present, we will perform network meta-analysis with random ef-
fects and inspect trial and participant characteristics for sources of
heterogeneity.
Assessment of reporting biases
Two authors (SJN and JW) will undertake a full risk of bias check
for each eligible study, including risk of reporting biases. In theory,
a review using IPD should overcome issues of reporting biases
as unpublished data can be provided and unpublished outcomes
calculated. We will assess potential selective reporting bias using
the ORBIT classification system (Kirkham 2010). As specified in
Data extraction andmanagement, wewill ask the data providers for
trial methods such as randomisation and blinding methods, and
we will discuss any missing data and inconsistencies with them.
Data synthesis
Wewill present all direct evidence visually via a treatment network
diagramof the 10 antiepileptic treatments. This treatment diagram
will have a maximum of direct 45 pairwise comparisons
We will take an intention-to-treat approach to analysis; in other
words, participants will be analysed in the group to which they
were randomised in an individual trial, irrespective of which treat-
ment they actually received. Therefore, for time-to-event out-
comes, ’time to six month remission’, ’time to 12 month remis-
sion’ and ’time to first seizure post randomisation’ participants will
not be censored if treatment was withdrawn. For the primary out-
come, time to withdrawal of allocated treatment, we will consider
withdrawals due to lack of efficacy (i.e. recurrent seizures), poor
tolerability (i.e. adverse events) or a combination of both poor ef-
ficacy and tolerability. Other withdrawals such as losses to follow
up, non-treatment related deaths, administrative trial reasons etc.
will be censored at the time of withdrawal.
For all time-to-event outcomes, wewill investigate the relationship
between the time-to-event and treatment effect of the anti-epilep-
tic drugs. We will use Cox proportional hazards regression models
will be used to obtain study-specific estimates of log(HR) or treat-
ment effect and associated standard errors. Themodel assumes that
ratio of hazards (risks) between the two treatment groups is con-
stant over time (i.e. hazards are proportional). This proportional
hazards assumption of the Cox regression model will be tested for
each outcome of each study by testing the statistical significance of
a time-varying covariate in the model for each study. If a violation
of this assumption is detected, we will perform sensitivity analy-
ses via interval censored (piecewise) Cox models. To preserve the
within-trial randomisation, we will stratify Cox regression models
by trial.
A key assumption made in networkmeta-analysis is that treatment
effect is “exchangeable” across all included trials; in other words,
the indirect comparison made between two treatments is a feasible
comparison to make (known as the transitivity assumption) and
that the indirect evidence is consistent with the direct evidence
where a comparison exists (known as the consistency assumption).
Transitivity requires that all treatments are “jointly randomisable”;
in other words, all 10 antiepileptic drugs could feasibly be ran-
domised in the same trial and those which are not treatment arms
in any given trial are “missing at random” (Lu 2006). This as-
sumption can not be formally tested statistically; transitivity must
be judged by careful consideration of trial settings and character-
istics, treatment mechanisms and participant demographics to in-
vestigate if any differences would be expected to modify relative
treatment effects. The consistency assumption can be evaluated
statistically via the Bucher Method (Bucher 1997), which applies
a z-test to the difference between the direct treatment effect esti-
mate and the indirect estimate for each loop of evidence. Given
the simplicity of this test, the influence of the precision of the
treatment effect estimate on the result of this test and the com-
plexity introduced by multi-arm trials and therefore association
between treatment effects estimated from arms of the same trial,
we will use a conservative significance threshold of 10% (P value
< 0.1) to judge the presence of heterogeneity. We will also evalu-
ate the presence of inconsistency statistically by comparing the fit
of the consistency model (the primary analysis model) to the in-
consistency model (the primary model adjusted for inconsistency
factors) (Higgins 2012; Lu 2006).
Wewill perform all analyses using statistical software packages SAS
(version 9.2) (Copyright, SAS Institute Inc. SAS and all other SAS
Institute Inc. product or service names are registered trademarks
or trademarks of SAS Institute Inc., Cary, NC, USA.), Stata soft-
ware version 11.2 (StataCorp 2009), or R version 2.13 (CRAN
2011). At the time of writing, a data access system is under de-
velopment to enable secure access to de-identified pharmaceutical
data from clinical trials (ClinicalStudyDataRequest.com) (https://
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clinicalstudydatarequest.com/Default.aspx). It is currently unclear
which format participant data held within this secure data access
system will in and therefore which statistical package(s) we will be
able to use for analysis. We anticipate this will become clear by the
time of analysis in the review.
For the 10 antiepileptic drugs included in the treatment network,
we are able to make 45 possible pairwise comparisons for both
partial and generalised onset seizures. For clinical interest and rel-
evance, we will present HR estimates for each antiepileptic drug
in the network compared to the current recommended first-line
treatments (carbamazepine or lamotrigine for partial onset seizures
and valproate for generalised onset seizures) in the main results of
this review via forest plots, and we will present the results for all
45 pairwise comparisons by seizure type as an ’Additional table’
for each outcome.
Subgroup analysis and investigation of heterogeneity
There are strong clinical beliefs that certain antiepileptic drugs
are more effective in certain seizure types than others, for exam-
ple carbamazepine is more effective in partial onset seizures and
valproate is more effective in generalised onset seizures (Marson
2000), suggesting that there is a treatment by seizure type (par-
tial or generalised) interaction; if such an interaction exists then
the key assumption of an exchangeable treatment effect across all
included trials would be violated. To account for this, we will
conduct all analyses separately by epilepsy type (partial onset or
generalised onset) according to the classification of main seizure
type at baseline. Partial seizures (simple or complex) and partial
secondarily generalised seizures are classified as partial epilepsy.
Primarily generalised seizures are classified as generalised epilepsy.
We will then judge exchangeability of treatment effect separately
by analyses of seizure type. If sufficient demographic participant
level data is made available to us, we will also consider stratified or
subgroup analyses according to participant covariates specified in
Data extraction and management as potential magnifiers of treat-
ment effect and as potential sources of heterogeneity and/or in-
consistency. Specifically, in addition to differences between seizure
types, wewould also like to explore differences in age of seizure on-
set (paediatric onset, adult onset, elderly onset), seizure frequency
before randomisation (time since first ever seizure and/or num-
ber of seizures before randomisation) and aetiology of seizures (if
known according to pre-treatment investigations such as EEG,
CT and/or MRI scan).
Sensitivity analysis
As discussed above (Data extraction and management), we will
discuss any inconsistencies in provided data with the correspond-
ing data providers. If large or major inconsistencies are present
which cannot be resolved by data providers, we will not include
the data in any analyses. If minor inconsistencies are present, we
will include the data in analyses and pursue sensitivity analyses
to test the robustness of results included in this data. The exact
sensitivity analyses we would perform would depend on the in-
consistency present.
Given thatmisclassification of seizure type is a recognised problem
in epilepsy (whereby some individuals with generalised seizures
have been mistakenly classed as having partial onset seizures and
vice versa) and such misclassification did impact upon the results
of a review in our series of pairwise reviews for monotherapy in
epilepsy comparing phenytoin and sodium valproate in which
nearly 50% of participants analysed may have had their seizure
type misclassified (Nolan 2013b), we intend to investigate the po-
tential impact of misclassification on results in a sensitivity analy-
sis. Given clinical evidence that individuals with generalised onset
seizures are unlikely to have an ’age of onset’ greater than 25 to
30 years (Malafosse 1994), we will examine the distribution of age
at onset for individuals with generalised seizures. We intend to
undertake two sensitivity analyses to investigate misclassification:
• re-classification of all individuals with generalised seizure
types and age at onset greater than 30 into an ’unclassified
seizure type’ group;
• re-classification of all individuals with generalised seizures
and age of onset greater than 30 as having partial onset seizures.
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A P P E N D I C E S
Appendix 1. Search strategy for the Cochrane Epilepsy Groups Specialised Register
#1 MeSH DESCRIPTOR Carbamazepine Explode All WITH AD AE AG AA AN AI BL CF CS CH CL CT DU EC HI IM IP ME
PK PD PO RE ST SD TU TO UR
#2 Carbamezepine OR CBZ OR SPD417 OR Apo-Carbamazepine OR Atretol OR Biston OR Calepsin OR Carbagen OR Car-
bamazepen OR Carbatrol OR Carbazepine OR Carbelan OR Epitol OR Equetro OR Finlepsin OR Karbamazepin OR Lexin OR
Neurotol OR Novo-Carbamaz OR Nu-Carbamazepine OR Sirtal OR Stazepin OR Stazepine OR Taro-Carbamazepine OR Tegretal
OR Tegretol OR Telesmin OR Teril OR Timonil
#3 #1 OR #2
#4 MeSH DESCRIPTOR Phenytoin Explode All WITH AD AE AG AA AN AI BL CF CS CH CL CT DU EC HI IM IP ME PK
PD PO RE ST SD TU TO UR
#5Dihydantoin ORDiphenylhydantoin ORDiphenylhydantoine ORDiphenylhydatanoinORFenitoina ORPhenytoine ORPheny-
toinum OR Aleviatin OR Antisacer OR Auranile OR Causoin OR Citrullamon OR Citrulliamon OR Comital OR Comitoina OR
Convul ORDanten ORDantinal OR Dantoinal OR Dantoine ORDenyl OR Di-Hydan ORDi-Lan ORDi-Phetine ORDidan OR
Difenilhidantoina OR Difenin OR Difetoin OR Difhydan OR Dihycon OR Dilabid OR Dilantin OR Dilantine OR Dillantin OR
Dintoin OR Dintoina OR Diphantoin OR Diphedal OR Diphedan OR Diphenat OR Diphenin OR Diphenine OR Dipheninum
ORDiphentoin ORDiphentyn ORDiphenylan ORDitoinate OR Ekko OR Elepsindon OR Enkelfel OR Epamin OR Epanutin OR
Epasmir OR Epdantoin OR Epdantoine OR Epelin OR Epifenyl OR Epihydan OR Epilan OR Epilantin OR Epinat OR Epised OR
Eptal OR Eptoin OR Fenantoin OR Fenidantoin OR Fentoin OR Fenylepsin OR Fenytoin OR Fenytoine OR Gerot-epilan-D OR
Hidan OR Hidantal OR Hidantilo OR Hidantina OR Hidantomin OR Hindatal OR Hydantal OR Hydantin OR Hydantoin OR
Hydantoinal OR Hydantol OR Ictalis OR Idantoil OR Idantoin OR Iphenylhydantoin OR Kessodanten OR Labopal OR Lehydan
OR Lepitoin OR Lepsin ORMesantoin ORMinetoin ORNeos-Hidantoina ORNeosidantoina ORNovantoina ORNovophenytoin
OR Om-hidantoina OR Om-Hydantoine OR Oxylan OR Phanantin OR Phanatine OR Phenatine OR Phenatoine OR Phenhydan
OR Phenhydanin OR Phenitoin OR Phentoin OR Phentytoin OR Phenytek OR Phenytex OR Ritmenal OR Saceril OR Sanepil
OR Silantin OR Sinergina OR Sodanthon OR Sodantoin OR Sodanton OR Solantin OR Solantoin OR Solantyl OR Sylantoic OR
Tacosal OR Thilophenyl OR TOIN OR Zentronal OR Zentropil OR PHT
#6 #4 OR #5
#7 MeSH DESCRIPTOR Valproic Acid Explode All WITH AD AE AG AA AN AI BL CF CS CH CL CT DU EC HI IM IP ME
PK PD PO RE ST SD TU TO UR
#8 Avugane OR Baceca OR Convulex OR Delepsine OR Depacon OR Depakene OR Depakine OR Depakote OR Deproic OR
Epiject OR Epilex OR Epilim OR Episenta OR Epival OR Ergenyl OR Mylproin OR Orfiril OR Orlept OR Selenica OR Stavzor
OR Valcote OR Valparin OR Valpro OR Valproate OR Valproic OR VPA
#9 #7 OR #8
#10 MeSH DESCRIPTOR Phenobarbital Explode All WITH AD AE AG AA AN AI BL CF CS CH CL CT DU EC HI IM IP ME
PK PD PO RE ST SD TU TO UR
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#11Fenobarbital ORPhenobarbitolORPhenobarbitoneOR “Phenobarbituric Acid”ORPhenylethylbarbiturateOR “Phenylethylbar-
bituric Acid” OR Phenylethylmalonylurea OR Adonal OR Aephenal OR Agrypnal OR Amylofene OR Aphenylbarbit OR Aphenylet-
ten OR Barbenyl OR Barbinal OR Barbiphen OR Barbiphenyl OR Barbipil OR Barbita OR Barbivis OR Barbonal OR Barbophen
OR Bardorm OR Bartol OR Bialminal OR Blu-Phen OR Cabronal OR Calmetten OR Calminal OR Cardenal OR Chinoin OR
Codibarbita OR Coronaletta OR Cratecil OR Damoral OR Dezibarbitur OR Dormina OR Dormiral OR Dormital OR Doscalun
OR Duneryl OR Ensobarb OR Ensodorm OR Epanal OR Epidorm OR Epilol OR Episedal OR Epsylone OR Eskabarb OR Etilfen
OR Euneryl OR Fenbital OR Fenemal OR Fenosed OR Fenylettae OR Gardenal OR Gardepanyl OR Glysoletten OR Haplopan
OR Haplos OR Helional OR Hennoletten OR Henotal OR Hypnaletten OR Hypnette OR Hypno-Tablinetten OR Hypnogen OR
Hypnolone OR Hypnoltol OR Hysteps OR Lefebar OR Leonal OR Lephebar OR Lepinal OR Lepinaletten OR Linasen OR Liquital
OR Lixophen OR Lubergal OR Lubrokal OR LumenOR Lumesettes OR LumesynOR Luminal OR Lumofridetten OR Luphenil OR
Luramin OR Molinal OR Neurobarb OR Nirvonal OR Noptil OR Nova-Pheno OR Nunol OR Parkotal OR Pharmetten OR Phen-
Bar OR Phenaemal OR Phenemal OR Phenemalum OR Phenobal OR Phenobarbyl OR Phenoluric OR Phenolurio OR Phenomet
OR Phenonyl OR Phenoturic OR Phenyletten OR Phenyral OR Phob OR Polcominal OR Prominal OR Promptonal OR Seda-
Tablinen OR Sedabar OR Sedicat OR Sedizorin OR Sedlyn OR Sedofen OR Sedonal OR Sedonettes OR Sevenal OR Sinoratox OR
Solfoton OR Solu-Barb OR Sombutol OR Somnolens OR Somnoletten OR Somnosan OR Somonal OR Spasepilin OR Starifen OR
Starilettae OR Stental OR Talpheno OR Teolaxin OR Teoloxin OR Thenobarbital OR Theoloxin OR Triabarb OR Tridezibarbitur
OR Triphenatol OR Versomnal OR Zadoletten OR Zadonal OR PB
#12 #10 OR #11
#13 Oxcarbazepine
#14 “GP 47680” OROCBZOROxcarbamazepine OR Actinium OR Barzepin OR Carbox ORDeprectal OR Lonazet OROxalepsy
OR Oxetol OR Oxpin OR Oxrate OR Oxtellar OR Oxypine OR Pharozepine OR Prolepsi OR Timox OR Trexapin OR Trileptal
OR Trileptin OR OXC
#15 #13 OR #14
#16 Lamotrigine
#17 “GW 273293” OR Lamotrigina OR Lamotriginum OR Lamictal OR Lamotrine OR Lamitrin OR Lamictin OR Lamogine OR
Lamitor OR LTG
#18 #16 OR #17
#19 Gabapentin
#20 Gabapentine OR Gabapentino OR Gabapentinum OR Gabapetin OR Aclonium OR Fanatrex OR Gabarone OR Neogab OR
Gralise OR Neurontin OR Novo-Gabapentin OR Nupentin OR GBP
#21 #19 OR #20
#22 Topiramate
#23 Tipiramate OR Topiramatum OR “Topiramic acid” OR Topamax OR TPM
#24 #22 OR #23
#25 Levetiracetam
#26 Levetiracetamum OR Levitiracetam OR Keppra OR LEV
#27 #25 OR #26
#28 Zonisamide
#29 Zonisamida OR Zonisamidum OR Zonegran OR Exceglan OR Excegram OR Excegran OR ZNS
#30 #28 OR #29
#31 #3 OR #6 OR #9 OR #12 OR #15 OR #18 OR #21 OR #24 OR #27 OR #30
#32 (adjunct* or “add-on” or “add on”) NOT monotherap*
#33 #31 NOT #32
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Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Carbamazepine] explode all trees
#2 Carbamezepine or CBZ or SPD417 or Apo-Carbamazepine or Atretol or Biston or Calepsin or Carbagen or Carbamazepen or
Carbatrol or Carbazepine or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol or Novo-Carbamaz or
Nu-Carbamazepine or Sirtal or Stazepin or Stazepine or Taro-Carbamazepine or Tegretal or Tegretol or Telesmin or Teril or Timonil
#3 #1 or #2
#4 MeSH descriptor: [Phenytoin] explode all trees
#5 Dihydantoin or Diphenylhydantoin or Diphenylhydantoine or Diphenylhydatanoin or Fenitoina or Phenytoine or Phenytoinum
or Aleviatin or Antisacer or Auranile or Causoin or Citrullamon or Citrulliamon or Comital or Comitoina or Convul or Danten or
Dantinal or Dantoinal or Dantoine or Denyl or Di-Hydan or Di-Lan or Di-Phetine or Didan or Difenilhidantoina or Difenin or
Difetoin or Difhydan or Dihycon or Dilabid or Dilantin or Dilantine or Dillantin or Dintoin or Dintoina or Diphantoin or Diphedal
or Diphedan or Diphenat or Diphenin or Diphenine or Dipheninum or Diphentoin or Diphentyn or Diphenylan or Ditoinate or Ekko
or Elepsindon or Enkelfel or Epamin or Epanutin or Epasmir or Epdantoin or Epdantoine or Epelin or Epifenyl or Epihydan or Epilan
or Epilantin or Epinat or Epised or Eptal or Eptoin or Fenantoin or Fenidantoin or Fentoin or Fenylepsin or Fenytoin or Fenytoine or
Gerot-epilan-D or Hidan or Hidantal or Hidantilo or Hidantina or Hidantomin or Hindatal or Hydantal or Hydantin or Hydantoin
or Hydantoinal or Hydantol or Ictalis or Idantoil or Idantoin or Iphenylhydantoin or Kessodanten or Labopal or Lehydan or Lepitoin
or Lepsin or Mesantoin or Minetoin or Neos-Hidantoina or Neosidantoina or Novantoina or Novophenytoin or Om-hidantoina or
Om-Hydantoine or Oxylan or Phanantin or Phanatine or Phenatine or Phenatoine or Phenhydan or Phenhydanin or Phenitoin or
Phentoin or Phentytoin or Phenytek or Phenytex or Ritmenal or Saceril or Sanepil or Silantin or Sinergina or Sodanthon or Sodantoin
or Sodanton or Solantin or Solantoin or Solantyl or Sylantoic or Tacosal or Thilophenyl or TOIN or Zentronal or Zentropil or PHT
#6 #4 or #5
#7 MeSH descriptor: [Valproic Acid] explode all trees
#8 Avugane or Baceca or Convulex or Delepsine or Depacon or Depakene or Depakine or Depakote or Deproic or Epiject or Epilex
or Epilim or Episenta or Epival or Ergenyl or Mylproin or Orfiril or Orlept or Selenica or Stavzor or Valcote or Valparin or Valpro or
Valproate or Valproic or VPA
#9 #7 or #8
#10 MeSH descriptor: [Phenobarbital] explode all trees
#11 Fenobarbital or Phenobarbitol or Phenobarbitone or “Phenobarbituric Acid” or Phenylethylbarbiturate or “Phenylethylbarbituric
Acid” or Phenylethylmalonylurea or Adonal or Aephenal or Agrypnal or Amylofene or Aphenylbarbit or Aphenyletten or Barbenyl or
Barbinal or Barbiphen or Barbiphenyl or Barbipil or Barbita or Barbivis or Barbonal or Barbophen or Bardorm or Bartol or Bialminal
or Blu-Phen or Cabronal or Calmetten or Calminal or Cardenal or Chinoin or Codibarbita or Coronaletta or Cratecil or Damoral or
Dezibarbitur or Dormina or Dormiral or Dormital or Doscalun or Duneryl or Ensobarb or Ensodorm or Epanal or Epidorm or Epilol
or Episedal or Epsylone or Eskabarb or Etilfen or Euneryl or Fenbital or Fenemal or Fenosed or Fenylettae or Gardenal or Gardepanyl
or Glysoletten or Haplopan or Haplos or Helional or Hennoletten or Henotal or Hypnaletten or Hypnette or Hypno-Tablinetten or
Hypnogen or Hypnolone or Hypnoltol or Hysteps or Lefebar or Leonal or Lephebar or Lepinal or Lepinaletten or Linasen or Liquital
or Lixophen or Lubergal or Lubrokal or Lumen or Lumesettes or Lumesyn or Luminal or Lumofridetten or Luphenil or Luramin
or Molinal or Neurobarb or Nirvonal or Noptil or Nova-Pheno or Nunol or Parkotal or Pharmetten or Phen-Bar or Phenaemal or
Phenemal or Phenemalum or Phenobal or Phenobarbyl or Phenoluric or Phenolurio or Phenomet or Phenonyl or Phenoturic or
Phenyletten or Phenyral or Phob or Polcominal or Prominal or Promptonal or Seda-Tablinen or Sedabar or Sedicat or Sedizorin or
Sedlyn or Sedofen or Sedonal or Sedonettes or Sevenal or Sinoratox or Solfoton or Solu-Barb or Sombutol or Somnolens or Somnoletten
or Somnosan or Somonal or Spasepilin or Starifen or Starilettae or Stental or Talpheno or Teolaxin or Teoloxin or Thenobarbital or
Theoloxin or Triabarb or Tridezibarbitur or Triphenatol or Versomnal or Zadoletten or Zadonal or PB
#12 #10 or #11
#13 Oxcarbazepine or “GP 47680” or OCBZ or Oxcarbamazepine or Actinium or Barzepin or Carbox or Deprectal or Lonazet or
Oxalepsy or Oxetol or Oxpin or Oxrate or Oxtellar or Oxypine or Pharozepine or Prolepsi or Timox or Trexapin or Trileptal or Trileptin
or OXC
#14 Lamotrigine or “GW 273293” or Lamotrigina or Lamotriginum or Lamictal or Lamotrine or Lamitrin or Lamictin or Lamogine
or Lamitor or LTG
#15 Gabapentin or Gabapentine or Gabapentino or Gabapentinum or Gabapetin or Aclonium or Fanatrex or Gabarone or Neogab or
Gralise or Neurontin or Novo-Gabapentin or Nupentin or GBP
#16 Topiramate or Tipiramate or Topiramatum or “Topiramic acid” or Topamax or TPM
#17 Levetiracetam or Levetiracetamum or Levitiracetam or Keppra or LEV
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#18 Zonisamide or Zonisamida or Zonisamidum or Zonegran or Exceglan or Excegram or Excegran or ZNS
#19 #3 or #6 or #9 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 (epilep* or seizure* or convuls*):ti,ab,kw (Word variations have been searched)
#21 MeSH descriptor: [Epilepsy] explode all trees
#22 MeSH descriptor: [Seizures] explode all trees
#23 (#20 or #21 or #22) in Trials
#24 #19 and #23
#25 (adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not monotherap*:ti (Word variations have been
searched)
#26 #24 not #25
Appendix 3. MEDLINE search strategy
1. exp Carbamazepine/
2. (Carbamezepine or CBZ or SPD417 or Apo-Carbamazepine or Atretol or Biston or Calepsin or Carbagen or Carbamazepen or
Carbatrol or Carbazepine or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol or Novo-Carbamaz or
Nu-Carbamazepine or Sirtal or Stazepin or Stazepine orTaro-Carbamazepine or Tegretal orTegretol or TelesminorTeril orTimonil).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier]
3. 1 or 2
4. exp Phenytoin/
5. (Dihydantoin or Diphenylhydantoin or Diphenylhydantoine or Diphenylhydatanoin or Fenitoina or Phenytoine or Phenytoinum
or Aleviatin or Antisacer or Auranile or Causoin or Citrullamon or Citrulliamon or Comital or Comitoina or Convul or Danten or
Dantinal or Dantoinal or Dantoine or Denyl or Di-Hydan or Di-Lan or Di-Phetine or Didan or Difenilhidantoina or Difenin or
Difetoin or Difhydan or Dihycon or Dilabid or Dilantin or Dilantine or Dillantin or Dintoin or Dintoina or Diphantoin or Diphedal
or Diphedan or Diphenat or Diphenin or Diphenine or Dipheninum or Diphentoin or Diphentyn or Diphenylan or Ditoinate or
Ekko or Elepsindon or Enkelfel or Epamin or Epanutin or Epasmir or Epdantoin or Epdantoine or Epelin or Epifenyl or Epihydan
or Epilan or Epilantin or Epinat or Epised or Eptal or Eptoin or Fenantoin or Fenidantoin or Fentoin or Fenylepsin or Fenytoin or
Fenytoine or Gerot-epilan-D or Hidan or Hidantal or Hidantilo or Hidantina or Hidantomin or Hindatal or Hydantal or Hydantin or
Hydantoin or Hydantoinal or Hydantol or Ictalis or Idantoil or Idantoin or Iphenylhydantoin or Kessodanten or Labopal or Lehydan
or Lepitoin or Lepsin or Mesantoin or Minetoin or Neos-Hidantoina or Neosidantoina or Novantoina or Novophenytoin or Om-
hidantoina or Om-Hydantoine or Oxylan or Phanantin or Phanatine or Phenatine or Phenatoine or Phenhydan or Phenhydanin or
Phenitoin or Phentoin or Phentytoin or Phenytek or Phenytex or Ritmenal or Saceril or Sanepil or Silantin or Sinergina or Sodanthon
or Sodantoin or Sodanton or Solantin or Solantoin or Solantyl or Sylantoic or Tacosal or Thilophenyl or TOIN or Zentronal or
Zentropil or PHT).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept, rare disease supplementary concept, unique identifier]
6. 4 or 5
7. exp Valproic Acid/
8. (Avugane or Baceca or Convulex or Delepsine or Depacon or Depakene or Depakine or Depakote or Deproic or Epiject or Epilex
or Epilim or Episenta or Epival or Ergenyl or Mylproin or Orfiril or Orlept or Selenica or Stavzor or Valcote or Valparin or Valpro or
Valproate or Valproic or VPA).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading
word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
9. 7 or 8
10. exp Phenobarbital/
11. (Fenobarbital or Phenobarbitol or Phenobarbitone or “Phenobarbituric Acid” or Phenylethylbarbiturate or “Phenylethylbarbituric
Acid” or Phenylethylmalonylurea or Adonal or Aephenal or Agrypnal or Amylofene or Aphenylbarbit or Aphenyletten or Barbenyl or
Barbinal or Barbiphen or Barbiphenyl or Barbipil or Barbita or Barbivis or Barbonal or Barbophen or Bardorm or Bartol or Bialminal
or Blu-Phen or Cabronal or Calmetten or Calminal or Cardenal or Chinoin or Codibarbita or Coronaletta or Cratecil or Damoral
or Dezibarbitur or Dormina or Dormiral or Dormital or Doscalun or Duneryl or Ensobarb or Ensodorm or Epanal or Epidorm or
Epilol or Episedal or Epsylone or Eskabarb or Etilfen or Euneryl or Fenbital or Fenemal or Fenosed or Fenylettae or Gardenal or
Gardepanyl or Glysoletten or Haplopan or Haplos or Helional or Hennoletten or Henotal or Hypnaletten or Hypnette or Hypno-
Tablinetten or Hypnogen or Hypnolone or Hypnoltol or Hysteps or Lefebar or Leonal or Lephebar or Lepinal or Lepinaletten or
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Linasen or Liquital or Lixophen or Lubergal or Lubrokal or Lumen or Lumesettes or Lumesyn or Luminal or Lumofridetten or
Luphenil or Luramin or Molinal or Neurobarb or Nirvonal or Noptil or Nova-Pheno or Nunol or Parkotal or Pharmetten or Phen-
Bar or Phenaemal or Phenemal or Phenemalum or Phenobal or Phenobarbyl or Phenoluric or Phenolurio or Phenomet or Phenonyl or
Phenoturic or Phenyletten or Phenyral or Phob or Polcominal or Prominal or Promptonal or Seda-Tablinen or Sedabar or Sedicat or
Sedizorin or Sedlyn or Sedofen or Sedonal or Sedonettes or Sevenal or Sinoratox or Solfoton or Solu-Barb or Sombutol or Somnolens
or Somnoletten or Somnosan or Somonal or Spasepilin or Starifen or Starilettae or Stental or Talpheno or Teolaxin or Teoloxin or
Thenobarbital or Theoloxin or Triabarb or Tridezibarbitur or Triphenatol or Versomnal or Zadoletten or Zadonal or PB).mp. [mp=
title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
12. 10 or 11
13. (Oxcarbazepine or “GP 47680” or OCBZ or Oxcarbamazepine or Actinium or Barzepin or Carbox or Deprectal or Lonazet or
Oxalepsy or Oxetol or Oxpin or Oxrate or Oxtellar or Oxypine or Pharozepine or Prolepsi or Timox or Trexapin or Trileptal or
Trileptin or OXC).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept, rare disease supplementary concept, unique identifier]
14. (Lamotrigine or “GW 273293” or Lamotrigina or Lamotriginum or Lamictal or Lamotrine or Lamitrin or Lamictin or Lamogine
or Lamitor or LTG).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept, rare disease supplementary concept, unique identifier]
15. (Gabapentin or Gabapentine or Gabapentino or Gabapentinum or Gabapetin or Aclonium or Fanatrex or Gabarone or Neogab
or Gralise or Neurontin or Novo-Gabapentin or Nupentin or GBP).mp. [mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
16. (Topiramate or Tipiramate or Topiramatum or “Topiramic acid” or Topamax or TPM).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept,
unique identifier]
17. (Levetiracetam or Levetiracetamum or Levitiracetam or Keppra or LEV).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique
identifier]
18. (Zonisamide or Zonisamida or Zonisamidum or Zonegran or Exceglan or Excegram or Excegran or ZNS).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
19. 3 or 6 or 9 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not monotherap$).ti.
21. 19 not 20
22. exp Epilepsy/
23. exp Seizures/
24. (epilep$ or seizure$ or convuls$).tw.
25. 22 or 23 or 24
26. exp Pre-Eclampsia/ or exp Eclampsia/
27. 25 not 26
28. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
29. clinical trials as topic.sh.
30. trial.ti.
31. 28 or 29 or 30
32. exp animals/ not humans.sh.
33. 31 not 32
34. 21 and 27 and 33
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Appendix 4. SCOPUS search strategy
(((TITLE (carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine OR atretol OR biston OR calepsin OR
carbagen OR carbamazepen OR carbatrol OR carbazepine OR carbelan OR epitol OR equetro OR finlepsin OR karbamazepin OR
lexinOR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine OR taro-carbamazepine OR tegretal
OR tegretol OR telesmin OR teril OR timonil OR phenytoin OR dihydantoin OR diphenylhydantoin OR diphenylhydantoine
OR diphenylhydatanoin OR fenitoina OR phenytoine OR phenytoinum OR aleviatin OR antisacer OR auranile OR causoin OR
citrullamon OR citrulliamon OR comital OR comitoina OR convul OR danten OR dantinal OR dantoinal OR dantoine OR denyl
OR di-hydan OR di-lan OR di-phetine OR didan OR difenilhidantoina OR difenin OR difetoin OR difhydan OR dihycon OR
dilabid OR dilantin OR dilantine OR dillantin OR dintoin OR dintoina OR diphantoin OR diphedal OR diphedan OR diphenat
OR diphenin OR diphenine OR dipheninum OR diphentoin OR diphentyn OR diphenylan OR ditoinate OR ekko OR elepsindon
OR enkelfel OR epamin OR epanutin OR epasmir OR epdantoin OR epdantoine OR epelin OR epifenyl OR epihydan OR epilan
OR epilantin OR epinat OR epised OR eptal OR eptoin OR fenantoin OR fenidantoin OR fentoin OR fenylepsin OR fenytoin
OR fenytoine OR gerot-epilan-d OR hidan OR hidantal OR hidantilo OR hidantina OR hidantomin OR hindatal OR hydantal OR
hydantin OR hydantoin OR hydantoinal OR hydantol OR ictalis OR idantoil OR idantoin OR iphenylhydantoin OR kessodanten
OR labopal OR lehydan OR lepitoin OR lepsin OR mesantoin OR minetoin OR neos-hidantoina OR neosidantoina OR novantoina
OR novophenytoin OR om-hidantoina OR om-hydantoine OR oxylan OR phanantin OR phanatine OR phenatine OR phenatoine
OR phenhydan OR phenhydanin OR phenitoin OR phentoin OR phentytoin OR phenytek OR phenytex OR ritmenal OR saceril
OR sanepil OR silantin OR sinergina OR sodanthon OR sodantoin OR sodanton OR solantin OR solantoin OR solantyl OR sylantoic
OR tacosal OR thilophenyl OR toin OR zentronal OR zentropil OR pht OR “Valproic Acid” OR avugane OR baceca OR convulex
OR delepsine OR depacon OR depakene OR depakine OR depakote OR deproic OR epiject OR epilex OR epilim OR episenta OR
epival OR ergenyl OR mylproin OR orfiril OR orlept OR selenica OR stavzor OR valcote OR valparin OR valpro OR valproate
OR valproic OR vpa OR phenobarbital OR fenobarbital OR phenobarbitol OR phenobarbitone OR “Phenobarbituric Acid” OR
phenylethylbarbiturate OR “Phenylethylbarbituric Acid” OR phenylethylmalonylurea OR adonal OR aephenal OR agrypnal OR
amylofene OR aphenylbarbit OR aphenylettenOR barbenyl OR barbinal OR barbiphen OR barbiphenyl OR barbipil OR barbita OR
barbivis OR barbonal OR barbophen OR bardorm OR bartol OR bialminal OR blu-phen OR cabronal OR calmetten OR calminal
OR cardenal OR chinoin OR codibarbita OR coronaletta OR cratecil OR damoral OR dezibarbitur OR dormina OR dormiral OR
dormital OR doscalun OR duneryl OR ensobarb OR ensodorm OR epanal OR epidorm OR epilol OR episedal OR epsylone OR
eskabarb OR etilfen OR euneryl OR fenbital OR fenemal OR fenosed OR fenylettae OR gardenal OR gardepanyl OR glysoletten OR
haplopan OR haplos OR helional OR hennoletten OR henotal OR hypnaletten OR hypnette OR hypno-tablinetten OR hypnogen
OR hypnolone OR hypnoltol OR hysteps OR lefebar OR leonal OR lephebar OR lepinal OR lepinaletten OR linasen OR liquital
OR lixophen OR lubergal OR lubrokal OR lumen OR lumesettes OR lumesyn OR luminal OR lumofridetten OR luphenil OR
luramin OR molinal OR neurobarb OR nirvonal OR noptil OR nova-pheno OR nunol OR parkotal OR pharmetten OR phen-
bar OR phenaemal OR phenemal OR phenemalum OR phenobal OR phenobarbyl OR phenoluric OR phenolurio OR phenomet
OR phenonyl OR phenoturic OR phenyletten OR phenyral OR phob OR polcominal OR prominal OR promptonal OR seda-
tablinen OR sedabar OR sedicat OR sedizorin OR sedlyn OR sedofen OR sedonal OR sedonettes OR sevenal OR sinoratox OR
solfoton OR solu-barb OR sombutol OR somnolens OR somnoletten OR somnosan OR somonal OR spasepilin OR starifen OR
starilettae OR stental OR talpheno OR teolaxin OR teoloxin OR thenobarbital OR theoloxin OR triabarb OR tridezibarbitur OR
triphenatol OR versomnal OR zadoletten OR zadonal OR pb OR oxcarbazepine OR “GP 47680” OR ocbz OR oxcarbamazepine OR
actinium OR barzepin OR carbox OR deprectal OR lonazet OR oxalepsy OR oxetol OR oxpin OR oxrate OR oxtellar OR oxypine
OR pharozepine OR prolepsi OR timox OR trexapin OR trileptal OR trileptin OR oxc OR lamotrigine OR “GW 273293” OR
lamotrigina OR lamotriginum OR lamictal OR lamotrine OR lamitrin OR lamictin OR lamogine OR lamitor OR ltg OR gabapentin
OR gabapentine OR gabapentino OR gabapentinum OR gabapetin OR aclonium OR fanatrex OR gabarone OR neogab OR gralise
OR neurontin OR novo-gabapentin OR nupentin OR gbp OR topiramate OR tipiramate OR topiramatum OR “Topiramic acid”
OR topamax OR tpm OR levetiracetam OR levetiracetamum OR levitiracetam OR keppra OR lev OR zonisamide OR zonisamida
OR zonisamidum OR zonegran OR exceglan OR excegram OR excegran OR zns)) OR (ABS(carbamazepine OR carbamezepine
OR cbz OR spd417 OR apo-carbamazepine OR atretol OR biston OR calepsin OR carbagen OR carbamazepen OR carbatrol OR
carbazepine OR carbelan OR epitol OR equetro OR finlepsin OR karbamazepin OR lexin OR neurotol OR novo-carbamaz OR
nu-carbamazepine OR sirtal OR stazepin OR stazepine OR taro-carbamazepine OR tegretal OR tegretol OR telesmin OR teril OR
timonil OR phenytoin OR dihydantoin OR diphenylhydantoin OR diphenylhydantoine OR diphenylhydatanoin OR fenitoina OR
phenytoine OR phenytoinum OR aleviatin OR antisacer OR auranile OR causoin OR citrullamon OR citrulliamon OR comital OR
comitoina OR convul OR danten OR dantinal OR dantoinal OR dantoine OR denyl OR di-hydan OR di-lan OR di-phetine OR
didan OR difenilhidantoina OR difenin OR difetoin OR difhydan OR dihycon OR dilabid OR dilantin OR dilantine OR dillantin
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OR dintoin OR dintoina OR diphantoin OR diphedal OR diphedan OR diphenat OR diphenin OR diphenine OR dipheninum
OR diphentoin OR diphentyn OR diphenylan OR ditoinate OR ekko OR elepsindon OR enkelfel OR epamin OR epanutin OR
epasmir OR epdantoin OR epdantoine OR epelin OR epifenyl OR epihydan OR epilan OR epilantin OR epinat OR epised OR eptal
OR eptoin OR fenantoin OR fenidantoin OR fentoin OR fenylepsin OR fenytoin OR fenytoine OR gerot-epilan-d OR hidan OR
hidantal OR hidantilo OR hidantina OR hidantomin OR hindatal OR hydantal OR hydantin OR hydantoin OR hydantoinal OR
hydantol OR ictalis OR idantoil OR idantoin OR iphenylhydantoin OR kessodanten OR labopal OR lehydan OR lepitoin OR lepsin
ORmesantoin ORminetoin OR neos-hidantoina OR neosidantoina OR novantoina OR novophenytoin OR om-hidantoina OR om-
hydantoine OR oxylan OR phanantin OR phanatine OR phenatine OR phenatoine OR phenhydan OR phenhydanin OR phenitoin
ORphentoin ORphentytoinOR phenytekORphenytexOR ritmenal OR saceril OR sanepil OR silantin OR sinergina OR sodanthon
OR sodantoin OR sodanton OR solantin OR solantoin OR solantyl OR sylantoic OR tacosal OR thilophenyl OR toin OR zentronal
OR zentropil OR phtOR “Valproic Acid”OR avugane ORbaceca OR convulex ORdelepsineORdepaconORdepakeneORdepakine
OR depakote OR deproic OR epiject OR epilex OR epilim OR episenta OR epival OR ergenyl OR mylproin OR orfiril OR orlept
OR selenica OR stavzor OR valcote OR valparin OR valpro OR valproate OR valproic OR vpa OR phenobarbital OR fenobarbital
OR phenobarbitol OR phenobarbitone OR “Phenobarbituric Acid” OR phenylethylbarbiturate OR “Phenylethylbarbituric Acid” OR
phenylethylmalonylurea OR adonal OR aephenal OR agrypnal OR amylofene OR aphenylbarbit OR aphenyletten OR barbenyl OR
barbinal OR barbiphen OR barbiphenyl OR barbipil OR barbita OR barbivis OR barbonal OR barbophen OR bardorm OR bartol
OR bialminal OR blu-phen OR cabronal OR calmetten OR calminal OR cardenal OR chinoin OR codibarbita OR coronaletta OR
cratecil OR damoral OR dezibarbitur OR dormina OR dormiral OR dormital OR doscalun OR duneryl OR ensobarb OR ensodorm
OR epanal OR epidorm OR epilol OR episedal OR epsylone OR eskabarb OR etilfen OR euneryl OR fenbital OR fenemal OR
fenosed OR fenylettae OR gardenal OR gardepanyl OR glysolettenOR haplopan OR haplos OR helional OR hennolettenOR henotal
OR hypnaletten OR hypnette OR hypno-tablinetten OR hypnogen OR hypnolone OR hypnoltol OR hysteps OR lefebar OR leonal
OR lephebar OR lepinal OR lepinaletten OR linasen OR liquital OR lixophen OR lubergal OR lubrokal OR lumen OR lumesettes
OR lumesyn OR luminal OR lumofridetten OR luphenil OR luramin OR molinal OR neurobarb OR nirvonal OR noptil OR nova-
pheno OR nunol OR parkotal OR pharmetten OR phen-bar OR phenaemal OR phenemal OR phenemalum OR phenobal OR
phenobarbyl OR phenoluric OR phenolurio OR phenomet OR phenonyl OR phenoturic OR phenyletten OR phenyral OR phob
OR polcominal OR prominal OR promptonal OR seda-tablinen OR sedabar OR sedicat OR sedizorin OR sedlyn OR sedofen OR
sedonal OR sedonettes OR sevenal OR sinoratox OR solfoton OR solu-barb OR sombutol OR somnolens OR somnoletten OR
somnosan OR somonal OR spasepilin OR starifen OR starilettae OR stental OR talpheno OR teolaxin OR teoloxin OR thenobarbital
OR theoloxin OR triabarb OR tridezibarbitur OR triphenatol OR versomnal OR zadoletten OR zadonal OR pb OR oxcarbazepine
OR “GP 47680” OR ocbz OR oxcarbamazepine OR actinium OR barzepin OR carbox OR deprectal OR lonazet OR oxalepsy OR
oxetol OR oxpin OR oxrate OR oxtellar OR oxypine OR pharozepine OR prolepsi OR timox OR trexapin OR trileptal OR trileptin
OR oxc OR lamotrigine OR “GW 273293” OR lamotrigina OR lamotriginum OR lamictal OR lamotrine OR lamitrin OR lamictin
OR lamogine OR lamitor OR ltg OR gabapentin OR gabapentine OR gabapentino OR gabapentinum OR gabapetin OR aclonium
OR fanatrex OR gabarone OR neogab OR gralise OR neurontin OR novo-gabapentin OR nupentin OR gbp OR topiramate OR
tipiramate OR topiramatum OR “Topiramic acid” OR topamax OR tpm OR levetiracetam OR levetiracetamum OR levitiracetam
OR keppra OR lev OR zonisamide OR zonisamida OR zonisamidum OR zonegran OR exceglan OR excegram OR excegran OR
zns))) AND ((TITLE-ABS-KEY(epilep*OR “infantile spasm” OR “ring chromosome 20” OR “R20” OR “myoclonic encephalopathy”
OR “pyridoxine dependency”) OR (TITLE-ABS-KEY(syndrome) W/2 (aicardi OR angelman OR doose OR dravet OR janz OR
jeavons OR “landau kleffner” OR “lennox gastaut” OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR “sturge weber”
OR tassinari OR “unverricht lundborg” OR west)) OR TITLE(seizure OR convuls*) OR (TITLE-ABS-KEY(lafora*) W/4 (disease
OR epilep*) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine)))) AND NOT (TITLE(*eclampsia) OR
INDEXTERMS(*eclampsia)) AND NOT INDEX(medl)) AND (TITLE(randomiz* OR randomis* OR controlled OR placebo OR
blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to head”) OR ABS(randomiz* OR
randomis* OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR
“head to head”) PRE/2 (trial OR method OR procedure OR study) AND NOT INDEX(medl))) AND NOT (TITLE((adjunct* OR
“add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*) AND NOT (monotherap* OR alone OR singl*)))
20Antiepileptic drug monotherapy for epilepsy: a network meta-analysis (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
SJN wrote the protocol under the supervision of AGM and CT. MS and JW commented on drafts of the protocol
D E C L A R A T I O N S O F I N T E R E S T
SJN and JW are funded as part of a three year research programme ‘Clinical and cost effectiveness of interventions for epilepsy in the
National Health Service (NHS)’ which receives financial support from the National Institute of Health Research (NIHR).
S O U R C E S O F S U P P O R T
Internal sources
• National Institute of Health Research, UK.
This review is funded as part of a research programme ‘Clinical and cost effectiveness of interventions for epilepsy in the National
Health Service (NHS)’ which receives financial support from the National Institute of Health Research (NIHR).
External sources
• No sources of support supplied
21Antiepileptic drug monotherapy for epilepsy: a network meta-analysis (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
